Journal of Surgical Oncology最新文献

Introduction: Elective neck dissection (END) for oral tongue squamous cell carcinoma (OTSCC) typically involves level 4 due to potential metastases that may bypass levels 1-2. Our study challenges this notion and investigates the necessity of level 4 inclusion in END for OTSCC.

Methods: A retrospective cohort study performed in a tertiary-care university affiliated medical center and included all OTSCC patients treated with END from 2000 to 2020, with a minimum 2-year follow-up. The study compared patients with END levels 1-3 to those with levels 1-4 regarding regional recurrence, disease-specific and disease-free survival rates.

Results: 120 patients with OTSCC and clinically negative neck were included. END included levels 1-4 in 33 patients (27.5%) and levels 1-3 in the remaining 87 patients (72.5%). Out of all 33 patients who underwent END of levels 1-4, only 1 patient had level 4 metastasis (3%). There was no significant difference in the regional recurrence rate (21.8% vs. 18.2%, p = 0.66) and level 4 recurrence rate (3.5% vs. 3%, p = 0.91) between the groups. No difference regarding 5-years overall, disease-specific, and disease-free survival was demonstrated between the 1-3 END and 1-4 END groups (69.3% vs. 61.1%, Log-rank p = 0.7, 82% vs. 66.2%, Log-rank p = 0.15% and 66.4% vs. 60.7%, Log-rank p = 0.54, respectively).

Conclusion: Inclusion of level 4 in the elective neck dissection for OTSCC does not seem to improve regional control, disease-free and overall survival. Hence, elective neck dissection of levels 1-3 seems appropriate for most cases of OTSCC, as for other oral cavity subsites.

Hanson, N., Farmer, W., Andres, M., Franko, J. and Le, V. (2025), Clinical Characteristics and Genomic Profile of Malignant Proliferating Trichilemmal Tumor: A Systematic Review of the Literature. Journal of Surgical Oncology, 131: 1074-1080. https://doi.org/10.1002/jso.27925

In Figure 1, the Prisma Flow Diagram, there was an error in the tabulated numbers. The final number of review articles was 29, but the number of removed articles stated 165. This was an error in calculation, and it was actually 163 from the original 192 to get 29.

The corrected figure is shown below.

We apologize for this error.

Filho GVdM, Costa GJ, Martins MR, Torres LC. Circulating levels of galectin-9 are a potential biomarker of survival in advanced non-small-cell lung cancer. J Surg Oncol. 2024; 130: 913-918. https://doi.org/10.1002/jso.27758.

In paragraph 2.1 of the Methods section, add a third paragraph to the text “The criteria for exclusion were pregnant or lactating patients, patients with psychiatric disorders, patients with a clinical history of HIV I/II or HTLV I/II infection, patients with a clinical history of autoimmune or infectious diseases, patients with a previous diagnosis and treatment for another type of malignant tumor and patients who had undergone prior chemotherapy, immunotherapy, or radiotherapy.

In paragraph 2.3 of the Methods section, remove the incorrect paragraph “A Kaplan–Meier curve with log-rank test was performed for survival time between sGal-9 ≤ 1,694 and > 1,694 groups and smoking status (smokers vs non-smokers)” and replace it with the text “The median survival time was calculated using a specific Gal9 cutoff value. The median survival using the Gal9 cutoff less than or equal to 1694 pg/mL was 15.9 months and undefined for the above cutoff point 1694 pg/mL.”

We apologize for these errors.

Introduction: The management of extremity soft tissue sarcomas (STS) involving major vessels presents unique challenges, historically leading to amputation. Advances in vascular reconstruction have enabled limb-sparing surgery (LSS), but outcomes and perioperative risks remain uncertain. This systematic review and meta-analysis aimed to evaluate oncologic results following LSS with vascular reconstruction in extremity STS.

Methods: A systematic review and single-arm meta-analysis were performed according to PRISMA guidelines, with registration in PROSPERO. PubMed, Embase, and Cochrane Library were searched from inception to June 2025 for studies reporting outcomes in patients with extremity STS undergoing LSS with vascular reconstruction. Pooled analyses estimated limb salvage, survival, and complication rates using random-effects models.

Results: Thirty-one studies comprising 520 patients were included. Approximately 58% were male, with a mean age ranging from 29.3 to 59 years. The most common tumor localizations were the thigh (59.5%), inguinal region (15.9%), and popliteal fossa (8.6%). Liposarcoma (24.0%), synovial sarcoma (19.6%), and osteosarcoma (14.8%) were the most frequent histological subtypes. The pooled limb salvage rate was 89% (95% CI, 86%-92%), while amputation occurred in 10% (95% CI, 8%-14%). One- and 5-year overall survival rates were 89% and 62%, respectively, with disease-free survival rates of 74% and 55%. Major complications included graft thrombosis (19%), wound complications (29%), and wound infection (22%).

Conclusions: Limb-sparing surgery with vascular reconstruction is effective for extremity STS involving major vessels, enabling high limb salvage and favorable long-term survival without compromising oncologic outcomes. However, substantial perioperative morbidity persists, underscoring the need for multidisciplinary care, careful patient selection, and prospective studies to refine indications and enhance quality of life.

This systematic review and meta-analysis assessed long-term outcomes following total pancreatectomy with islet autotransplantation (TPIAT). Seventeen studies including 1332 patients were analyzed. The pooled insulin independence rate was 34%, with higher rates for non-chronic pancreatitis indications (68%) versus chronic pancreatitis (33%). TPIAT is effective in preserving endocrine function. Further studies are needed to validate outcomes across extended indications and to standardize reporting, incorporating metabolic markers and patient-reported quality-of-life endpoints over long-term follow-up.

Oesophageal carcinoma is a rising global health burden, with surgical resection and perioperative chemotherapy forming the cornerstone of curative treatment. However, uncertainty persists regarding the optimal surgical approach, partly due to heterogeneity in outcome reporting, which hinders data synthesis and evidence-based decision-making. To address this, a core outcome set (COS) for oesophageal cancer surgery was developed through international consensus among clinicians and patients. This study systematically evaluates the uptake of these core outcomes in contemporary surgical research. A systematic review was conducted of randomised controlled trials and prospective cohort studies investigating oesophagectomy for oesophageal cancer, published between 2010 and 2024. The reporting of ten COS-recommended outcomes was assessed across eligible studies. Fifty-eight studies involving 22 260 patients were included (39 cohort studies; 19 RCTs). No study reported all 10 core outcomes. The median number of core outcomes reported was 4 (interquartile range 3-5). The frequency of individual core outcome reporting was as follows: in-hospital mortality (86%), conduit necrosis/leak (81%), respiratory complications (79%), overall survival (30%), ability to eat and drink (44%), quality of life (26%), inoperability (23%), reflux symptoms (21%), severe nutritional effects (19%), and need for reintervention (16%). No improvement in core outcome reporting was observed over the study period. Promoting COS implementation and improving methodological rigour is essential to ensure that future research reflects the priorities of both clinicians and patients, and facilitates meaningful evidence synthesis.